Borrelia burgdorferi Antibodies, Total by ELISA, CSF
0099483
Ordering Recommendation
Use in conjunction with positive serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.
Mnemonic
LYME CSF
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Sun - Sat
Reported
1-3 days  
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
CSF.  
Specimen Preparation
Transfer 3 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Contaminated or heat-inactivated specimens.  
Remarks
  
Stability
Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)  
Reference Interval
0.99 LIV or less: Negative - Antibody to Borrelia burgdorferi not detected.
1.00-1.20 LIV: Equivocal - Repeat testing in 10-14 days may be helpful.
1.21 LIV or greater: Positive - Probable presence of antibody to Borrelia burgdorferi detected.  
Interpretive Data
The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocal and positive results with Western blot. Both IgM and IgG Western blots should be performed on samples less than four weeks after appearance of erythema migrans. Only IgG Western blot should be performed on samples greater than four weeks after the disease onset. IgM Western blot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate Western blot testing within 10 days.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
Once this test is performed, if:
a) Negative - no further testing is done.
b) Positive or equivocal - Western blot testing will be performed on the original sample upon receiving a request. Sample will be held for 30 days only.
CPT Code(s)
86618
Components
Component Test Code*Component Chart Name
0099483Borrelia burgdorferi Abs, ELISA, CSF
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Lyme Antibodies, Total
  • Lyme Disease
  • Lyme Disease Ab CSF, ELISA